Galectin Therapeutic (GALT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 09-2010 | 06-2010 | 03-2010 | 12-2009 | 09-2009 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 2,810 | 2,860 | 120 | 250 | 460 |
| Other current assets | 50 | 70 | 50 | 50 | 60 |
| TOTAL | $2,860 | $2,930 | $170 | $300 | $520 |
| Non-Current Assets | |||||
| Other Non-Current Assets | 100 | 100 | 100 | 100 | 260 |
| TOTAL | $100 | $100 | $100 | $100 | $260 |
| Total Assets | $2,980 | $3,050 | $300 | $430 | $810 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 180 | 100 | 170 | 220 | 490 |
| Accrued Expenses | 580 | 930 | 710 | 830 | 570 |
| TOTAL | $770 | $1,030 | $880 | $1,050 | $1,060 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 1,450 | 1,900 | 2,760 | 1,930 | 2,440 |
| TOTAL | $1,450 | $1,900 | $2,760 | $1,930 | $2,440 |
| Total Liabilities | $2,220 | $2,940 | $3,640 | $2,980 | $3,500 |
| Shareholders' Equity | |||||
| Common Shares | 60 | 50 | 50 | 50 | 50 |
| Retained earnings | -54,900 | -53,000 | -50,530 | -47,710 | -46,400 |
| Other shareholders' equity | 4,220 | 3,690 | 3,100 | 2,580 | 2,070 |
| TOTAL | $750 | $110 | $-3,340 | $-2,550 | $-2,690 |
| Total Liabilities And Equity | $2,970 | $3,050 | $300 | $430 | $810 |